Evidence map›Paper›PMID 42511563›Full record

ArticleInternational journal of molecular sciences2026

Therapeutic Window for Intravenous Human Muse Cell Administration in Mouse Spinal Cord Injury.

Kotaro Sakashita, Yoshihiro Kushida, Shohei Wakao, Hiroshi Takahashi, Yasuhiro Horibata, Shun Okuwaki, Yosuke Ogata, Takane Nakagawa, Takahiro Sunami, Hisanori Gamada and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kotaro SakashitaDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.ORCID 0000-0002-3662-2077
Yoshihiro KushidaDepartment of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan.
Shohei WakaoDepartment of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan.
Hiroshi TakahashiDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Yasuhiro HoribataDepartment of Biochemistry, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan.
Shun OkuwakiDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.ORCID 0000-0002-9614-5399
Yosuke OgataDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Takane NakagawaDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Takahiro SunamiDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.ORCID 0000-0002-5513-7114
Hisanori GamadaDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Tomoaki ShimizuDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Toru FunayamaDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Kousei MiuraDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
Hiroshi NoguchiDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.ORCID 0000-0001-9426-7731
Hiroyuki SugimotoDepartment of Biochemistry, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan.
Masashi YamazakiDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.ORCID 0000-0002-9293-3531
Mari DezawaDepartment of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan.
Masao KodaDepartment of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.

Funding

AO Spine National Research Grant AOSRG2023033General Insurance Association of Japan No grant number assignedJapan Society for the Promotion of Science 20K09494JST SPRING JPMJSP2124
6 · The paper itself

Abstract

Stage-specific embryonic antigen-3-positive pluripotent-like/macrophage-like multilineage-differentiating stress-enduring (Muse) cells are a distinct subpopulation of mesenchymal stromal cells (MSCs), accounting for 1% to several percent of MSCs. Although stem cell therapy for spinal cord injury (SCI) typically targets the subacute phase to avoid the hostile acute environment, the therapeutic window for Muse cells remains unclear. C57BL/6J mice with severe T9 contusion SCI received a single tail vein injection of human bone marrow-derived (BM) Muse cells, BM-MSCs (both 5 × 10

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationSpinal Cord InjuriesAnimalsCell DifferentiationDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLRecovery of Functionintravenous administrationmesenchymal stromal cellsMuse cellssphingosine-1-phosphatespinal cord injurytherapeutic window

Identifiers

PMID42511563
PMCPMC13409780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.